{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:41:27Z","timestamp":1792978887225,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40265-024-02110-8","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:02:27Z","timestamp":1730757747000},"page":"1481-1485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Vunakizumab: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"1","key":"2110_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","volume":"87","author":"C Zhang","year":"2022","unstructured":"Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87(1):95\u2013102.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2110_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, Krueger GG, Paek SY, et al. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11(2):385\u2013400.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"2110_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103638","volume":"23","author":"F Proft","year":"2024","unstructured":"Proft F, Duran TI, Ghoreschi K, et al. Treatment strategies for spondyloarthritis: implementation of precision medicine - or \u201cone size fits all\u201d concept? Autoimmun Rev. 2024;23(10): 103638.","journal-title":"Autoimmun Rev"},{"key":"2110_CR4","unstructured":"Committee on Psoriasis Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573-625."},{"key":"2110_CR5","unstructured":"Jiangsu Hengrui Medicine Co Ltd. Milestone in chronic disease innovation! Hengrui's first autoimmune innovative drug, vunakizumab, was approved for marketing [media release]. 27 Aug 2024. https:\/\/www.hengrui.com\/."},{"key":"2110_CR6","volume-title":"Vunakizumab: Chinese prescribing information","author":"Suzhou Suncadia Biopharmaceutical Co Ltd","year":"2024","unstructured":"Suzhou Suncadia Biopharmaceutical Co Ltd. Vunakizumab: Chinese prescribing information. Suzhou: Suzhou Suncadia Biopharmaceutical Co Ltd; 2024."},{"key":"2110_CR7","unstructured":"Jiangsu Hengrui Medicine Co Ltd. Hengrui Medicine's innovative drug vunakizumab is approved for clinical trials for the treatment of moderate to severe plaque psoriasis in children and adolescents. [media release]. 8 Aug 2024. https:\/\/www.hengrui.com\/."},{"key":"2110_CR8","unstructured":"Jiangsu Hengrui Medicine Co Ltd. R & D pipeline. 2024. https:\/\/www.hengrui.com\/en\/pipeline.html. Accessed 23 Sep 2024."},{"key":"2110_CR9","unstructured":"Xu J, Yan K, Han L, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial [abstract no. 115]. In: 32nd EADV Congress 2023. 2023."},{"key":"2110_CR10","doi-asserted-by":"crossref","unstructured":"Huang F, Zhu J, Zhao C, et al. Vunakizumab in active ankylosing spondylitis: a randomized, double-blind, adaptive, seamless, phase 2\/3 study [abstract no. POS0803]. Ann Rheum Dis. 2024;83(Suppl 1):904-905.","DOI":"10.1136\/annrheumdis-2024-eular.868"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02110-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02110-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02110-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T22:42:54Z","timestamp":1732747374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02110-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02110-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"10 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}